5873-11-0

Usage

Uses

Used in Pharmaceutical Industry:
3-HYDROXY-2-(TOLUENE-4-SULFONYLAMINO)-PROPIONIC ACID is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
3-HYDROXY-2-(TOLUENE-4-SULFONYLAMINO)-PROPIONIC ACID is used as a building block in the synthesis of complex organic molecules. Its reactivity and functional groups make it a valuable precursor for creating a wide range of chemical products.
Used in Antimicrobial Applications:
3-HYDROXY-2-(TOLUENE-4-SULFONYLAMINO)-PROPIONIC ACID is used as an antimicrobial agent for its ability to inhibit the growth of microorganisms. This property makes it a potential candidate for use in the development of new antibiotics and antifungal agents, which are essential in combating drug-resistant infections.
Used in Research and Development:
3-HYDROXY-2-(TOLUENE-4-SULFONYLAMINO)-PROPIONIC ACID is used as a research tool in various scientific studies. Its unique structure and properties make it an interesting subject for exploring new chemical reactions, understanding biological processes, and developing innovative applications in different industries.

InChI:InChI=1/C10H13NO5S/c1-7-2-4-8(5-3-7)17(15,16)11-9(6-12)10(13)14/h2-5,9,11-12H,6H2,1H3,(H,13,14)

Upstream product

• 302-84-1 serin 
• 98-59-9 p-toluenesulfonyl chloride 
• 5873-11-0 3-hydroxy-2-{(4-methylphenyl)sulphonamino}propanoic acid 
• 56-45-1 L-serin 

Downstream Products

• 7663-92-5 N-tosyl-L-serine 
• 5873-13-2 (R)-2-(p-Tolylsulfonamido)serine 
• 80613-82-7 3-(N-tosyl-DL-Ser)aminocoumarin 
• 152877-85-5 2-(p-toluenesulfonylamino)propane-1,3-diol 
• 91958-80-4 (S)-4-acetoxymethyl-3-(toluene-4-sulfonyl)-oxazolidin-5-one 
• 382653-95-4 N-(1-hydroxymethyl-2-oxo-decyl)-4-methyl-benzenesulfonamide 
• 873442-03-6 (S)-N-(p-toluene-sulphonyl)-O-(tert-butyldiphenylsilyl)-serine 
• 382653-97-6 (R)-2-Nonyl-1-(toluene-4-sulfonyl)-aziridine 
• 382653-96-5 N-(1-hydroxymethyl-decyl)-4-methyl-benzenesulfonamide 
• 943304-43-6 N-[2-hydroxy-1-(2-octyl-[1,3]dithian-2-yl)-ethyl]-4-methyl-benzenesulfonamide 

Relevant academic research and scientific papers

Palladium(II) mixed-ligand complexes containing 2,2′-bipyridine derivatives and 4-toluenesulfonyl-l-serine: Synthesis, characterization, and crystal structure determination

The 4-toluenesulfonyl-L-serine ligand (1), (tsserH2), was prepared from the reaction of L-serine and 4-toluenesulfonyl chloride in sodium hydroxide solution 1 M. The complexes [Pd(4,4′-dmbipy)(tsser)] (2) and [Pd(5,5′-dmbipy)(tsser)].0.5CH

Pd(II)-Catalyzed Aminofluorination of Alkenes in Total Synthesis 6-(R)-Fluoroswainsonine and 5-(R)-Fluorofebrifugine

The total syntheses of two fluorinated alkaloids, 6-(R)-fluoroswainsonine and 5-(R)-fluorofebrifugine, are described. Both encompass (4aS,7R,8aR)-7-fluoro-5-tosylhexahydro-4H-[1,3]dioxino[5,4-b]pyridine as a key synthon which is obtained through a further

Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy

AIMP2-DX2, a splicing variant of AIMP2, is up-regulated in lung cancer, possesses oncogenic activity, and results in tumorigenesis. Specifically inhibiting the interaction between AIMP2-DX2 and HSP70 to suppress AIMP2-DX2-dependent cancers with small molecules is considered a promising avenue for cancer therapeutics. Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors. Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay. Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination. More importantly, BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.

Synthesis, molecular docking and pharmacological investigation of some 4-methylphenylsulphamoyl carboxylic acid analogs

Compounds bearing sulphonyl and amino acid moieties are considered the basis for sulfa drug development. The synthesis of 4-methylphenylsulphamoyl carboxylic acids and the evaluation of their pharmacological activities are reported. The synthesis of these

Iodine-Catalyzed Synthesis of Chiral 4-Imidazolidinones Using α-Amino Acid Derivatives via Dehydrogenative N-H/C(sp3)-H Coupling

An efficient method for the asymmetric synthesis of 4-imidazolidinones via an iodine-catalyzed intramolecular N-H/C(sp3)-H activation of readily available and abundant feedstocks, amino acids, and amines is described. The reaction proceeded under visible light irradiation to afford a variety of 4-imidazolidinone derivatives under mild conditions in moderate to excellent yields. Secondary and tertiary C(sp3)-H bonds were aminated, and various functional groups were tolerated.

New carboxamides bearing benzenesulphonamides: Synthesis, molecular docking and pharmacological properties

Ten new derivatives of benzenesulphonamide bearing carboxamide functionality were synthesized and investigated for their in vitro antimicrobial, antioxidant and in vivo anti-inflammatory activities. Compound 9d inhibited carrageenan induced rat-paw oedema

Pd(II)-Catalyzed Aminofluorination of Alkenes in Total Synthesis 6-(R)-Fluoroswainsonine and 5-(R)-Fluorofebrifugine

The total syntheses of two fluorinated alkaloids, 6-(R)-fluoroswainsonine and 5-(R)-fluorofebrifugine, are described. Both encompass (4aS,7R,8aR)-7-fluoro-5-tosylhexahydro-4H-[1,3]dioxino[5,4-b]pyridine as a key synthon which is obtained through a further

The effect of hydrogen bond on Br?nsted acid-catalyzed intramolecular hydroamination of unfunctionalized olefins

The catalytic activity of benzoic acid could be increased by introducing a hydrogen bond donor group at the ortho-position. Preliminary DFT calculation indicated that the activation of CC double bond was realized by the action of both the carboxyl group and the hydrogen bond donor. The amino group was brought to the activated CC bond by the interaction between the carboxyl oxygen and amino proton. This interaction also increased the nucleophilicity of the amino group. Thus, in the presence of 20 mol % of 2-(trifluoromethanesulfonamido)benzoic acid, intramolecular hydroamination of unfunctionalized olefins gave the corresponding products in up to 95% isolated yields.

Development of amino acid conjugated sulfonamides as potent antiulcer agent

A series of 2-{[(4-methylphenyl) sulfonyl] amino}-3-sulfanylpropanoic acid (1a) and its analogs 1b-j have been synthesized. These compounds were screened for their in vivo efficacy in pyloric ligation model. Compounds 1a and 1b with higher antiulcer potential were further screened in other gastric models to explore the mode of antiulcer action. To further understand the mode of action, in vitro inhibition of H+/K+ ATPase activity in gastric microsome isolated from rat stomach was studied. This was rationalized by in silico experiments.

Synthesis, characterization, and cytotoxicity of platinum(II)/palladium(II) complexes with 4-toluenesulfonyl-L-amino acid dianion and diimine/diamine

Eight new platinum(II)/palladium(II) complexes with 4-toluenesulfonyl-L- amino acid dianion and diimine/diamine ligands, [Pd(en)(Tsile)]·H 2O (1), [Pd(bipy)(Tsile)] (2), [Pd(bipy)(Tsthr)]·0.5H 2O (3), [Pd(phen)(Tsile)]·0.5H2O (4), [Pd(phen)(Tsthr)]·H2O (5), [Pd(bqu)(Tsthr)]·1.5H 2O (6), [Pt(en)(Tsser)] (7), and [Pt(en)(Tsphe)]·H 2O (8), have been synthesized and characterized by elemental analyses, 1H NMR and mass spectrometry. The crystal structure of 7 has been determined by X-ray diffraction. Cytotoxicities were tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and sulforhodamine B assays. The complexes exert cytotoxicity against HL-60, Bel-7402, BGC-823, and KB cell lines with 4 having the best cytotoxicity against HL-60, Bel-7402, and BGC-823 cell lines; the compounds are less cytotoxic than cisplatin.